文献速递耳科与耳神经

射波刀立体定向放射外科治疗进展性前庭神经鞘瘤:纵向肿瘤控制、听力结局及治疗后听力状态预测

CyberKnife Stereotactic Radiosurgery for Growing Vestibular Schwannoma: Longitudinal Tumor Control, Hearing Outcomes, and Predicting Post-Treatment Hearing Status.
PubMed 文献 · Laryngoscope · 2023-05-13

回顾性病例系列纳入127例影像学证实进展性前庭神经鞘瘤接受射波刀立体定向放射外科治疗的患者,肿瘤控制率为94.5%;109例听力分析中,治疗前AAO-HNS A级和B级患者分别有33.3%和26.9%维持原听力分级,随访超过60个月者仅15.3%维持A或B级;预测模型含年龄、眼底帽距离、肿瘤体积和耳蜗最大辐射剂量,仅眼底帽距离有统计学意义。

要点

  • 射波刀治疗进展性前庭神经鞘瘤的肿瘤控制率为94.5%。
  • 治疗前A级和B级听力者分别有33.3%和26.9%维持原分级。
  • 随访超过60个月者仅15.3%维持A或B级听力。

核心结论

  • 射波刀立体定向放射外科是控制前庭神经鞘瘤的有效治疗。
  • 按听力分级,约三分之一患者得以保留听力。
  • 眼底帽距离对听力损失具有保护作用。

研究设计与样本

  • 回顾性病例系列 review,纳入127例影像学证实为进展性前庭神经鞘瘤并接受射波刀立体定向放射外科治疗的患者。
  • 肿瘤通过线性测量和三维分段体积分析(3D-SVA)进行影像学随访。
  • 对109例患者进行听力结局分析,采用Cox比例风险模型识别与听力结局相关的变量。

主要发现

  • 射波刀治疗前庭神经鞘瘤的肿瘤控制率为94.5%。
  • 截至末次可获取的听力图,治疗前AAO-HNS A级患者中33.3%维持A级,治疗前B级患者中26.9%维持B级。
  • 随访超过60个月且治疗前为A级或B级的患者中,15.3%维持在同一A或B分组内。
  • 最终预测听力结局的模型包括年龄、眼底帽距离(FCD)、肿瘤体积和耳蜗最大辐射剂量,但仅FCD有统计学显著性。

关键数值与推荐

  • 听力结局采用美国耳鼻咽喉头颈外科学会(AAO-HNS)分级系统分类。
  • 肿瘤控制率为94.5%。
  • 治疗前A级患者维持A级比例为33.3%,治疗前B级患者维持B级比例为26.9%。
  • 随访超过60个月且治疗前A或B级患者维持同一分组比例为15.3%。
  • 预测模型中仅FCD有统计学显著性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: (1) To determine tumor control rates for treating growing vestibular schwannoma (VS) with CyberKnife stereotactic radiosurgery (CK SRS); (2) to determine hearing outcomes after CK SRS; (3) to propose a set of variables that could be used to predict hearing outcomes for patients receiving CK SRS for VS. STUDY DESIGN: Retrospective case series review. METHODS: 127 patients who received CK SRS for radiographically documented growing VS were reviewed. Tumors were monitored for post-procedure growth radiographically with linear measurements and three-dimensional segmental volumetric analysis (3D-SVA). Hearing outcomes were reviewed for 109 patients. Cox proportional hazard modeling was used to identify variables correlated with hearing outcomes. RESULTS: Tumor control rate was 94.5% for treating VS with CK SRS. Hearing outcomes were categorized using the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) classification system. As of their last available audiogram, 33.3% of patients with pre-treatment class A and 26.9% of patients with class B retained their hearing in that class. 15.3% of patients starting with class A or B with extended follow-up (>60 months), maintained hearing within this same grouping. Our final model proposed to predict hearing outcomes included age, fundal cap distance (FCD), tumor volume, and maximum radiation dose to the cochlea; however, FCD was the only statistically significant variable. CONCLUSION: CK SRS is an effective treatment for control of VS. Hearing preservation by class was achieved in a third of patients. Finally, FCD was found to be protective against hearing loss. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:S1-S12, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Hildrew DM, Perez PL, Mady LJ, et al. CyberKnife Stereotactic Radiosurgery for Growing Vestibular Schwannoma: Longitudinal Tumor Control, Hearing Outcomes, and Predicting Post-Treatment Hearing Status. Laryngoscope. 2023. PMID: 37178050. doi:10.1002/lary.30731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。